Oxford BioDynamics Plc (OBD.L)
LSE · GBp · Healthcare · Diagnostics & Research
£0.122 (+3.83%) as of
Key statistics
- Market cap
- 16.40M
- Forward P/E
- -0.30
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.0800 – 0.3400
- Beta
- -0.17
- Revenue (TTM)
- 1.2M
- Profit margin
- 0.00%
- Analyst target
- £0.30
- Volume
- 2.87M
About Oxford BioDynamics Plc
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch Orion, a cloud platform, running on google cloud architecture; and EpiSwitch Explorer Array Kit platform, enabling advanced analysis of 3D regulatory control points. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Oxford, United Kingdom
- Employees
- 37
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.